Biocity receives IND approval from FDA for its FIC ADC BC3195

On February 13, 2023 Biocity Biopharma reported that the U.S. Food and Drug Administration (FDA) has granted the company’s Investigational New Drug (IND) application for the investigational drug BC3195 (CDH3 ADC) (Press release, Biocity Biopharmaceutics, FEB 13, 2023, View Source [SID1234633307]). The approval enables Biocity Biopharma to conduct the phase 1 study of BC3195 in Patients with Locally Advanced or Metastatic Solid Tumors in the United States. This is the second US IND approval in the past few months, which is another important milestone for Biocity Biopharma in its effort to extend product development globally.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BC3195 is a novel ADC targeting CDH3/P-cadherin, a calcium-dependent cell-cell adhesion glycoprotein expressed in a variety of malignancies, including lung, breast, gastric, ovarian, colorectal, and pancreatic cancers.
CDH3 is highly expressed in malignant tumors with low or no expression in normal tissues, which makes it an ideal target to develop anticancer treatment, particularly for the development of ADCs.
In preclinical study, BC3195 binds to cell surface CDH3 and is efficiently internalized. In different animal models, BC3195 demonstrated good safety profile and strong antitumor activities with tumor growth inhibition reaching up to 100%.
BC3195 a first-in-class new generation ADC designed with a clinically validated linker and payload (MMAE) that has bystander effect.
Currently, BC3195 is the only ADC targeting CDH3 in clinical development globally.Biocity Biopharma believes that BC3195 may hold the promise of becoming a novel treatment for patients with advanced cancers where high unmet medical needs still exist.